ClinicalTrials.gg
Active, not recruitingNCT06550076Updated Jun 2, 2026

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

A Phase 3 interventional study of TAK-279 in Plaque Psoriasis, sponsored by Takeda. Active, not recruiting at 278 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,099
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
7th of 673
2,099 · median 77
Started
2024
with 15 others
Phase 3
188 of 764
6 open now
Primary completion
2029-08
later than 71 of 85 live
Registered
717th of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 7th largest by enrollment of the 673 interventional ones that give a count, is one of 16 that started in 2024, is one of 188 in phase 3, reaches primary completion later than 71 of the 85 other live ones, and was the 717th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis.

All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules.

Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.

Read the detailed description

This study consists of 2 parts: Part A and Part B.

Part A: Participants who did not participate in one of the parent studies (TAK-279-3001 [NCT06088043], TAK-279-3002 [NCT06108544], or TAK-279-PsO-3004 [NCT06973291]) may be enrolled and will be treated for up to 52 weeks. Participants who successfully complete Part A of the study are eligible to continue in Part B, but investigators must confirm their eligibility to continue in Part B.

Part B: Participants who complete the treatment period of TAK-279-3001 (NCT06088043), TAK-279-3002 (NCT06108544), or TAK-279-PsO-3004 (NCT06973291) parent studies or who complete Part A are eligible to enroll directly into open label extension treatment in Part B and will be treated for up to 156 weeks.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Latitude Psoriasis 3
  • Latitude Research Program
  • Latitude PsO OLE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

Part A:

  • Participant is willing and able to understand and fully comply with study procedures and requirements (including digital tools and applications), in the opinion of the investigator.
  • Participant has provided written and any required privacy authorization before the initiation of any study procedures.
  • Participant is aged 18 years or older at the time of consent.
  • Participant has a diagnosis of chronic plaque psoriasis for >=6 months prior to the screening visit.
  • Participant has stable plaque psoriasis defined as no significant flare or change in morphology (as assessed by the investigator) in psoriasis for >=6 months before screening.
  • Participant has moderate-to-severe plaque psoriasis as defined by a PASI score >=12 and a sPGA score >=3 at screening and Day 1.
  • Participant has plaque psoriasis covering >=10% of his or her total BSA at screening and Day 1.
  • Participant must be a candidate for phototherapy or systemic therapy.

Part B:

- Participant has completed 52 weeks of treatment (TAK-279-3001 or Part A) or 60 weeks of treatment (TAK-279-3002), or 16 weeks of treatment (TAK-279-PsO-3004) in their parent study.

Main Exclusion Criteria

Part A:

  • Participant has evidence of non-plaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis). If a participant meets criteria for inclusion based on typical plaque psoriasis presentation, a limited amount of inverse psoriasis is not exclusionary.
  • Participant requires systemic treatment, other than nonsteroidal anti-inflammatory drugs, during the trial period for an immune-related disease (e.g., inflammatory bowel disease).
  • Participant has any medical condition, evidence of an unstable clinical condition (e.g., cardiovascular, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or immunologic), or vital signs/physical/laboratory/ abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results. These include but are not limited to:

    1. Participant has a history of known or suspected condition/illness that is consistent with compromised immunity, including but not limited to any identified congenital or acquired immunodeficiency; splenectomy.
    2. Participant had a major surgery within 60 days prior to Day 1 or has a major surgery planned during the study.
    3. Participant has unstable, poorly controlled, or severe hypertension at screening, confirmed by 2 repeat assessments.
    4. Participant has a history of Class III or IV congestive heart failure as defined by criteria.
    5. Participant has a history of cancer or lymphoproliferative disease, with the exception of successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix.
    6. For participants with asthma, , or other pulmonary illnesses, participant has been hospitalized in the past 3 months, has ever required intubation for treatment, currently requires oral , or has required more than 1 course of oral corticosteroids within 6 months prior to Day 1.
    7. Participant has any of the following cardiovascular disease history: A new diagnosis of atrial fibrillation or an episode of atrial fibrillation with rapid ventricular response or other dysrhythmia, non-acute cardiac hospitalization (e.g., pacemaker implantation), pulmonary embolism, or deep venous thrombosis within the past 6 months prior to screening. Any history of cerebrovascular event, myocardial infarction, coronary stenting, or aortocoronary bypass surgery. If, however, the investigator determines there are no suitable treatment alternatives available for the participant and it has been at least 6 months since the occurrence of any such event, the participant may enroll.
    8. Participant has ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if he or she participated in the study, in the opinion of the investigator.
    9. Participant has significant/uncontrolled psychiatric illness, in the opinion of the investigator.
    10. Participant has any lifetime history of suicidal ideation, suicidal behavior, or suicidal attempts by 1) medical history; or 2) by Columbia-Suicide Severity Rating Scale (C-SSRS) documentation at screening or by answering "yes" to Question 5 for suicidal ideation on the C-SSRS at screening; or 3) is clinically deemed to have a suicide risk by the investigator.
    11. Participant has a patient health questionnaire - 8 (PHQ-8) score of 15 or above at screening.
    12. Participant has a history of clinically significant drug or alcohol abuse within 12 months prior to Day 1.
  • Participant has received any of the following biologics or biosimilar versions within the time frame indicated or 5 half-lives, whichever is longer:

    1. Antibodies to interleukin (IL) -12/-23, IL-17, or IL-23 (eg, ustekinumab, secukinumab, tildrakizumab, ixekizumab, or guselkumab) within 6 months prior to Day 1.
    2. Tumor necrosis factor inhibitor(s) (e.g., etanercept, adalimumab, infliximab, certolizumab) within 2 months prior to Day 1.
    3. Agents that modulate integrin pathways to impact lymphocyte trafficking (e.g., natalizumab) or agents that modulate B cells or T cells (e.g., alemtuzumab, abatacept, or visilizumab) within 3 months prior to Day 1.
    4. Rituximab or other immune cell-depleting therapy within 6 months prior to Day 1.
  • Participant has any previous exposure to TAK-279 (also known as NDI-034858) or other TYK2 inhibitors, including deucravacitinib, or participant participated in any study that included a TYK2 inhibitor (e.g., deucravacitinib, VTX958, GLPG3667, etc.), unless the participant has documentation of post-trial unblinding that confirms the partcipant did not receive a TYK2 inhibitor.
  • Participant has a known or suspected allergy to TAK-279 or any of its components.

Part B:

  • Participant has completed the parent study or Part A but was permanently discontinued from treatment.
  • Participant had evidence of significant noncompliance with study visits or study drug in the parent study or Part A, as defined in the parent study protocol or in the opinion of the investigator.
  • Participant has met criteria for termination from the parent study or Part A, regardless of whether or not the participant was terminated from the parent study or Part A.
  • Participant has developed evidence of non-plaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis) since enrollment in the parent study or Part A.
  • Participant has developed a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments.
  • Participant has received a prohibited psoriasis treatment during the parent study or Part A, whether or not that treatment was documented as a concomitant medication and is expected to continue that treatment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
2,099 participants (actual)

Study arms

  • Experimental
    Part A (De Novo Cohort) + Part B (Open Label Extension): TAK-279

    Part A: Participants will receive TAK-279, oral tablet once daily (QD) for up to 52 weeks. Part B: Participants who completed the treatment period of parent studies (TAK-279-3001 \[NCT06088043\], TAK-279-3002 \[NCT06108544\], or TAK-279-PsO-3004 \[NCT06973291\]) or who completed Part A will receive TAK-279, oral tablet QD for up to 156 weeks.

    Drug: TAK-279

Interventions

06

What researchers measure

Primary outcomes

  1. Part A and Part B: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE)

    A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. An SAE is any untoward medical occurrence that at any dose: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event in the opinion of the healthcare provider, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above. TEAEs consist of both serious and non-serious adverse events.

    Time frame: From start of the drug administration up to Week 56 (Part A) and Week 160 (Part B)

Secondary outcomes

  1. Part A and B: Number of Participants Achieving 75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI-75) Score

    The PASI is a composite score based on the degree of effect on body surface area of psoriasis and extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. The PASI-75 is defined as 75% improvement from baseline in PASI score.

    Time frame: Baseline up to Week 52 (Part A) and Week 156 (Part B)

  2. Part A and B: Number of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a >=2-point Decrease from Baseline

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA composite score ranges from 0 to 4 and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean greater than (\>) 0, less than (\<) 1.5; Mild (2) = mean greater than or equal to (\>=) 1.5, \<2.5; Moderate (3) = mean \>=2.5, \<3.5; and Severe (4) = mean \>=3.5.

    Time frame: Baseline up to Week 52 (Part A) and Week 156 (Part B)

07

Study locations

278 sites
  • Total Dermatology
    Birmingham, Alabama 35205, United States
  • University of Alabama Hospital - Whitaker Clinic -
    Birmingham, Alabama 35233-2110, United States
  • Cahaba Dermatology Skin Health Center
    Hoover, Alabama 35244-2111, United States
  • Medical Dermatology Specialists
    Phoenix, Arizona 85006, United States
  • Saguaro Dermatology Associates, LLC - Probity - PPDS
    Phoenix, Arizona 85008-3884, United States
  • Noble Clinical Research
    Tucson, Arizona 85704, United States
  • Johnson Dermatology Clinic
    Fort Smith, Arkansas 72916-6103, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913-6475, United States
  • Zenith Research, Inc.
    Beverly Hills, California 90212, United States
  • First OC Dermatology Research Inc.
    Fountain Valley, California 92708, United States
  • Center for Dermatology Clinical Research
    Fremont, California 94538, United States
  • Long Beach Research Institute
    Long Beach, California 90805, United States
  • Metropolis Dermatology Downtown LA - Probity - PPDS
    Los Angeles, California 90017-5310, United States
  • UCLA University of California Los Angeles
    Los Angeles, California 90024, United States
  • Northridge Clinical Trials
    Northridge, California 91325-4122, United States
  • UC Davis Dermatology Clinic
    Sacramento, California 95816-3370, United States
  • TCR Medical Corporation
    San Diego, California 92123-1523, United States
  • University Clinical Trials
    San Diego, California 92123, United States
  • Dermatology Institute and Skin Care Center
    Santa Monica, California 90404-2216, United States
  • UNISON Clinical Trials (Shahram Jacobs md inc.)
    Sherman Oaks, California 91403, United States
  • Driven Research LLC
    Coral Gables, Florida 33134-3901, United States
  • Revival Research Corporation - Florida - ClinEdge - PPDS
    Doral, Florida 33122-1902, United States
  • FXM Clinical Research Ft. Lauderdale, LLC
    Fort Lauderdale, Florida 33308-5211, United States
  • Direct Helpers Medical Center
    Hialeah, Florida 33012, United States
  • Florida Academic Centers Research
    Miami, Florida 33136-1003, United States
  • FXM Clinical Research Miami, LLC
    Miami, Florida 33175-3582, United States
  • San Marcus Research Clinic Inc
    Miami Lakes, Florida 33014, United States
  • FXM Research Miramar
    Miramar, Florida 33027-4714, United States
  • Renstar Medical Research -21 NE 1st Ave
    Ocala, Florida 34470, United States
  • Lenus Research & Medical Group
    Sweetwater, Florida 33172, United States
  • Advanced Clinical Research Institute (ACRI) - Florida
    Tampa, Florida 33607-6429, United States
  • Divine Dermatology and Aesthetics, LLC
    Atlanta, Georgia 30315-2042, United States
  • Marietta Dermatology & The Skin Cancer Center - Marietta
    Marietta, Georgia 30060-7902, United States
  • Advanced Medical Research, PC
    Sandy Springs, Georgia 30328, United States
  • Georgia Skin and Cancer Clinic
    Savannah, Georgia 31419-1768, United States
  • Leavitt Clinical Research
    Idaho Falls, Idaho 83404-8322, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008-3811, United States
  • NorthShore Medical Group Dermatology - Skokie
    Skokie, Illinois 60077-1049, United States
  • DS Research - 1005 E. Lewis & Clark Pkwy Indiana Location
    Clarksville, Indiana 47129-2201, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • Skin Sciences, PLLC
    Louisville, Kentucky 40217-1444, United States
  • Dermatology Specialists Research - 3810 Springhurst Blvd
    Louisville, Kentucky 40241-6162, United States
  • Lawrence J Green, MD LLC
    Rockville, Maryland 20850, United States
  • University of Michigan Hospital - 1500 E Medical Center Dr
    Ann Arbor, Michigan 48109-5360, United States
  • Oakland Hills Dermatology - 3400 Auburn Rd
    Auburn Hills, Michigan 48326-3396, United States
  • Revival Research Corporation - ClinEdge
    Troy, Michigan 48084-3536, United States
  • Minnesota Clinical Study Center
    New Brighton, Minnesota 55112, United States
  • Skin Specialists PC
    Omaha, Nebraska 68144, United States
  • Henderson Clinical Trials
    Henderson, Nevada 89052, United States
  • Dartmouth Hitchcock Medical Center - Old Etna Rd
    Lebanon, New Hampshire 03766-1937, United States
  • ALLCUTIS Research, LLC.
    Portsmouth, New Hampshire 03801, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • Sadick Research Group
    New York, New York 10075-0385, United States
  • Montefiore AOA - BRANY
    The Bronx, New York 10467, United States
  • Accellacare of Cary
    Cary, North Carolina 27518, United States
  • The Skin Surgery Center for Clinical Research - Objective Health - PPDS
    Winston-Salem, North Carolina 27103-7109, United States
  • Bexley Dermatology Research - Probity - PPDS
    Bexley, Ohio 43209, United States
  • Wright State Physicians
    Fairborn, Ohio 45324, United States
  • Apex Clinical Research Center
    Mayfield Heights, Ohio 44124-4005, United States
  • Oregon Medical Research Center PC
    Portland, Oregon 97201, United States
  • University of Pittsburgh Medical Center-3601 5th Ave
    Pittsburgh, Pennsylvania 15213-3403, United States
  • Cumberland Skin Center for Clinical Research - Objective Health - PPDS
    Hermitage, Tennessee 37076-3497, United States
  • International Clinical Research US LLC
    Murfreesboro, Tennessee 37130-2450, United States
  • Arlington Research Center
    Arlington, Texas 76011-3800, United States
  • Bellaire Dermatology Associates
    Bellaire, Texas 77401-3505, United States
  • UT Physicians Dermatology - Bellaire Station
    Bellaire, Texas 77401, United States
  • Modern Research Associates
    Dallas, Texas 75231-6077, United States
  • North Texas Center for Clinical Research
    Frisco, Texas 75034, United States
  • San Antonio
    San Antonio, Texas 78213-2250, United States
  • Texas Dermatology and Laser Specialists-San Antonio-7703 Floyd Curl Dr
    San Antonio, Texas 78218-3128, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229-3409, United States
  • Houston Center for Clinical Research, LLC
    Sugar Land, Texas 77479-1001, United States
  • Center For Clinical Studies, LTD. LLP - 451 N Texas Ave
    Webster, Texas 77598-4927, United States
  • Virginia Clinical Research - 6160 Kempsville Cir
    Norfolk, Virginia 23507, United States
  • Conexa Investigación Clínica S.A.
    Buenos Aires, Ciudad Autónoma de BuenosAires C1012, Argentina
  • Centro de Investigaciones Médicas Tucumán
    San Miguel de Tucumán, Tucumán Province T4000, Argentina
  • Centro de Investigacion Clinica
    Ciudad Autónomade Buenos Aires, C1060ABN, Argentina
  • St George Dermatology and Skin Cancer Center - Probity - PPDS
    Kogarah, New South Wales 2217, Australia
  • The Skin Center - Probity
    Benowa, Queensland 4217, Australia
  • Skin Health Institute Inc - Probity - PPDS
    Carlton, Victoria 3053, Australia
  • Alfred Health
    Parkville, Victoria 3050, Australia
  • Western Health - Sunshine Hospital
    Parkville, Victoria 3050, Australia
  • Medical Center Unimed EOOD-Sevlievo
    Sevlievo, Gabrovo 5400, Bulgaria
  • Medical Center Asklepii OOD
    Dupnitsa, Kyustendil 2600, Bulgaria
  • Diagnostic and Consulting Center Aleksandrovska EOOD
    Sofia, Sofia-Grad 1431, Bulgaria
  • Diagnostic Consultative Centre - Focus-5 - LZIP EOOD
    Sofia, Sofia-Grad 1463, Bulgaria
  • Medical Center Hera EOOD-Sofia
    Sofia, Sofia-Grad 1510, Bulgaria
  • Diagnostic Consultative Center XXVIII - Sofia - EOOD
    Sofia, Sofia-Grad 1592, Bulgaria
  • Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia
    Sofia, Sofia-Grad 1606, Bulgaria
  • MC Comac Medical
    Sofia, Sofia-Grad 1612, Bulgaria
  • Multiprofile Hospital For Active Treatment Dr Tota Venkova
    Gabrovo, Bulgaria
  • Diagnostic Consultative Center Sveti
    Haskovo, 6300, Bulgaria
  • Medical Center Medconsult Pleven OOD
    Pleven, Bulgaria
  • Beacon Dermatology - Probity
    Calgary, Alberta T3A 2N1, Canada
  • Dermatology Research Institute, Inc.
    Calgary, Alberta T3A 2N1, Canada
  • Alberta DermaSurgery Centre - Probity
    Edmonton, Alberta T6G 1C2, Canada
  • VIDA Dermatology - Probity
    Edmonton, Alberta T6H 4J8, Canada
  • Care Clinic
    Red Deer, Alberta T4P 1K4, Canada
  • Enverus Medical Research - Probity
    Surrey, British Columbia V3V 0C6, Canada
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3E 0V9, Canada

Showing the first 100 of 278 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Aug 2029, 59 months after the start.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 59 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 12, 2024
StartActual
Sep 4, 2024
Primary completionEst.
Aug 5, 2029
CompletionEst.
Aug 5, 2029
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06550076
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Sep 4, 2024
Primary completion
Aug 5, 2029 (estimated)
Completion
Aug 5, 2029 (estimated)
Last update
Jun 2, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zasocitinib

Start the discussion